Anticancer Effect of Quercetin and Ribociclib Combination in SNU-1 Gastric Cancer Cell Line

Abstract

Objective: Gastric cancer is a significant malignancy worldwide, associated with high mortality rates. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, which play a role in regulating the cell cycle, have emerged as promising targeted agents in cancer therapy.

Methods: In this study, the cytotoxic effects of the CDK4/6 inhibitor ribociclib and the natural flavonoid quercetin were evaluated on the human gastric cancer cell line SNU-1. Ribociclib and quercetin were administered individually and in combination at varying concentrations. Following 24 hours of incubation, cytotoxicity was assessed using the XTT cell viability assay.

Results: Ribociclib significantly reduced cell viability when administered alone in the gastric cancer cell line. Quercetin alone did not exhibit a statistically significant cytotoxic effect. In ribocycicib-quercetin combination application, it was observed that quercetin suppressed the cytotoxic effect of ribocycicib at some doses at 100 and 50 µM concentrations.

Conclusion: These findings suggest that ribociclib is effective against gastric cancer cells; however, its combination with quercetin may limit its therapeutic efficacy.